Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer

Cancer Research

Volumn 57, Issue 23, 1997, Pages 5281-5285

  Crew, Jeremy P ^a,b,c   O'Brien, Tim ^a,b,c   Bradburn, Mike ^c   Fuggle, Sue ^b   Bicknell, Roy ^a   Cranston, David ^b,c   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ARTICLE; BLADDER CANCER; CANCER STAGING; CLINICAL ARTICLE; DNA FLANKING REGION; ENZYME ACTIVITY; GENE TARGETING; HUMAN; IMMUNOCYTOCHEMISTRY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR UPREGULATION; RELAPSE; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE; VASCULAR ENDOTHELIUM;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; REFERENCE VALUES; RNA, MESSENGER; SURVIVAL RATE; TIME FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030678133     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Folkman, J. What is the evidence that tumours are angiogenesis dependent? N. Engl. J. Med., 285: 82-86, 1990.
2. Ferrara, N., and Davis-Smyth, T. D. The biology of vascular endothelial growth factor. Endocr. Rev., 10: 4-25, 1997.
3. Dickinson, A. J., Fox, S. B., Persad, R. A., Hollyer, J., Sibley, G. N., and Harris, A. L. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br. J. Urol., 74: 762-766, 1994.
4. Bochner, B., Cote, R., Groshen, S., Esrig, D., Freeman, J., Weidner, N., Chen, S-C., Skinner, D., and Nichols, P. Angiogenesis in bladder cancer: relationship between microvessel density and tumour prognosis. J. Natl. Cancer Inst., 87: 1603-1612, 1995.
5. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, R., and Harris, A. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res., 55: 510-513, 1995.
6. Crew, J. P., O'Brien, T. S., and Harris, A. L. Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Cancer Metastasis Rev., 15: 221-230, 1996.
7. 1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol., 153: 1823-1827, 1995.
8. Esrig, D., Elmajian, D., Groshen, S., Freeman, J., Stein, J., Chen, S-C., Nicholls, P., Skinner, D., Jones, P., and Cote, R. Accumulation of nuclear p53 and tumour progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
9. Esrig, D., Spruck, C. D., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A., and Cote, R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143: 1389-1397, 1993.
10. Chomczynski, P., and Saachi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
11. Sacks, N. P. M., Smith, K., Norman, A. P., Greenall, M., Lejeune, S., and Harris, A. L. Cathepsin D levels in primary breast cancer: relationship with epidermal growth factor receptor, oestrogen receptor and axillary node status. Eur. J. Cancer, 29A: 426-428, 1993.
12. Scott, P. A. E., Smith, K., Bicknell, R., and Harris, A. L. A reliable external control for ribonuclease protection assays. Nucleic Acids Res., 25: 1305-1306, 1997.
13. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedure. J. Histochem. Cytochem., 29: 577-580, 1981.
14. Habuchi, T., Takahashi, R., Yamada, H., Kakehi, Y., Sugiyama, T., and Yoshida, O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet, 342: 1087-1088, 1993.
15. Melder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., and Jain, R. K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumour endothelium. Nat. Med., 2: 992-997, 1996.
16. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumours inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103, 1996.
17. De Benedetti, A., and Rhoads, R. E. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc. Natl. Acad. Sci. USA, 87: 8212-8216, 1990.
18. Kevil, C. G., De Benedetti, A., Payne, D. K., Coe, L. L., Laroux, F. S., and Alexander, J. S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumour angiogenesis. Int. J. Cancer, 65: 785-790, 1996.
19. O'Brien, T. S., Crew, J. P., Cranston, D., Bicknell, R., and Harris, A. L. Two mechanisms of basic fibroblast growth factor induced angiogenesis in bladder cancer. J. Urol., 155: 689A, 1996.
20. Gasparini, G., Weidner, N., Maluta, S., Pozza, F., Boracchi, P., Mezzetti, M., Testolin, A., and Bevilacqua, P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer, 55: 739-744, 1993.
21. Van Meir, E. G., Polverini, P. J., Chazin, V. R., Huang, H-J. S., de Tribolet, N., and Cavenee, W. K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet., 8: 171-176, 1994.
22. Dameron, K., Volpert, O., Tainsky, M., and Bouck, N. Control of angiogenesis by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994.
23. Mukhopadhyay, D., Tsiokas, L., and Sukhatme, V. P. Wild-type p53 and v-SRC exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res., 55: 6161-6165, 1995.
24. Keiser, A., Weich, H. A., Brandner, G., Marme, D., and Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
25. Saleh, M., Stacker, S. A., and Wilks, A. F. Inhibition of growth of C6 glionia cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res., 56: 393-401, 1996.
26. Kim, K. J., Li, B., Houck, K., Winer, J., and Ferrara, N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 7: 53-64, 1992.
27. Pesenti, E., Sola, F., Mongelli, N., Grandi, M., and Spreafico, F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br. J. Cancer, 66: 367-372, 1992.
28. Olander, J. V., Connolly, D. T., and DeLarco, J. E. Specific binding of vascular permeability factor to endothelial cells. Biochem. Biophys. Res. Commun., 175: 68-76, 1991.
29. Walther, M. M., Trahan, E. E., Cooper, M., Venzon, D., and Linehan, W. M. Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines. J. Urol., 152: 1599-1602, 1994.
30. Eisenberger, M., Reyno, L., Jodrell, D., Sinibaldi, V., Tkaczuk, K., Sridhara, R., Zukhowski, E., Lowitt, M., Jacobs, S., and Egorin, M. Suramin, an active drug for prostate cancer: interim observations in a Phase I trial. J. Natl. Cancer Inst., 85: 611-621, 1993.
31. Walther, M. M., Figg, W. D., and Lineham, W. M. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J. Urol., 14: S8-S11, 1996.